feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Real-World Study: Many Keep Weight Off After Stopping GLP-1s

Real-World Study: Many Keep Weight Off After Stopping GLP-1s

22 Jan

•

Summary

  • Most patients maintained or lost more weight 18 months after stopping GLP-1 drugs.
  • Exercise counseling significantly increased likelihood of maintaining weight loss.
  • Real-world data contrasts with clinical trial findings on weight regain.
Real-World Study: Many Keep Weight Off After Stopping GLP-1s

Real-world evidence indicates that a significant portion of patients using GLP-1 drugs, such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, can sustain weight loss after stopping treatment. This contrasts with findings from clinical trials that suggested substantial weight regain upon discontinuation.

An analysis of over 135,000 patients found that among those who stopped tirzepatide, about 36% maintained their weight loss and another 36% continued to lose weight six months later. For semaglutide users, 32% maintained weight loss and 35% continued to lose weight in the same timeframe.

Researchers noted that patients who received exercise counseling after their last prescription were nearly twice as likely to maintain weight loss. This suggests that behavior changes, possibly combined with lasting physiological effects from the drugs, could contribute to durable weight management.

trending

Salesforce lays off 1000

trending

India US trade tariffs slashed

trending

Margot Robbie's Wuthering Heights panned

trending

CBSE board exams: key details

trending

Jana Nayagan movie court case

trending

Dhakshineswar Suresh Davis Cup hero

trending

Deepika Padukone wears Gaurav Gupta

trending

NZ vs UAE match prediction

trending

iPhone 17 Croma Valentine's sale

While acknowledging study limitations, experts suggest these findings may pave the way for personalized obesity treatment plans. These plans could better identify individuals who can safely discontinue medication, require intermittent use, or need sustained treatment to preserve metabolic health.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
While some real-world data suggests weight loss can be sustained after stopping GLP-1 drugs, it's not guaranteed for everyone, and further research is ongoing.
The nference analysis examined real-world patient data to understand weight regain trends after discontinuing GLP-1 medications.
Yes, patients who received exercise counseling after stopping GLP-1 treatment were significantly more likely to maintain weight loss.

Read more news on

Healthside-arrow

You may also like

Ozempic's New Secret: Healing Joints Beyond Weight Loss

16 hours ago • 5 reads

article image

Weight Loss Drug Sparks Unexpected Pregnancies

1 Feb • 81 reads

article image

Blindness, Ruptured Colon: Lawsuits Target Ozempic

28 Jan • 114 reads

article image

Novo, Lilly clash in $700M ad war

28 Jan • 99 reads

article image

Passenger Weight Loss Saves Airlines Millions

19 Jan • 167 reads

article image